author-photo

Owen A OConnor

University of Virginia

16

Papers

86

Citations

Citation Trend

Filter By

Papers (13) Sort By

Journal Conference Others

Tolinapant (ASTX660), a Non-Peptidomimetic Antagonist of cIAP1/2 and XIAP, and the HDAC Inhibitor Romidepsin Are Synergistic in in Vitro Models of T Cell Lymphoma

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Targeting the T-Cell Lymphoma Epigenome Induces Cell Death, Cancer Testes Antigens, Immune-Modulatory Signaling Pathways.

2021 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (0)
A Real World Experience of Combined Treatment with Romidepsin and Azacitidine in Patients with Peripheral T-Cell Lymphoma

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
TCL-150: The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (1)
Peripheral T-Cell Lymphoma Involvement of the Central Nervous System: Impact of Novel Therapeutics on Clinical Outcomes

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
R-loop-Mediated ssDNA Breaks Accumulate Following Short-Term Exposure to the HDAC Inhibitor Romidepsin.

2021 Molecular Cancer Research
Show All
- Source
- Cite
- Save
Citations (2)
ECHELON-2 (NCT01777152), a randomized, double-blind, phase 3 study of brentuximab vedotin plus cyclophosphamide doxorubicin and prednisone versus cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with CD30-positive peripheral T-cell lymphoma: 5-year results

2021 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (0)
Final Results of a Phase 1 Study of Loncastuximab Tesirine in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.

2020 Blood
Show All
- Source
- Cite
- Save
Citations (32)
The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma

2020 Blood
Show All
- Source
- Cite
- Save
Citations (7)
Targeting MYD88-Mutant DLBCL with IRAKIMiDs: A Comparison to IRAK4 Kinase Inhibition and Evaluation of Synergy with Rational Combinations

2020 Blood
Show All
- Source
- Cite
- Save
Citations (0)